NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
STAVUDINE; LAMIVUDINE; NEVIRAPINE (stavudine; lamivudine; nevirapine) by Aspen Pharmacare is 12. Approved for human immunodeficiency virus (hiv)-1 infection [see ].
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STAVUDINE; LAMIVUDINE; NEVIRAPINE is a fixed-dose combination of three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for HIV-1 infection. This triple-agent regimen suppresses viral replication by inhibiting HIV reverse transcriptase through complementary mechanisms. The combination is designed for adult and pediatric patients, offering simplified dosing via oral tablet administration.
Pre-Launch
Pre-launch stage suggests emerging opportunity; product team will focus on regulatory clearance, market access, and launch planning with moderate initial headcount.
Mechanism of Action
12.1 Mechanism of Action Stavudine is an antiviral drug [see ]. 12.3 Pharmacokinetics The pharmacokinetics of stavudine have been evaluated in HIV-1-infected adult and pediatric patients (, , and ). Peak plasma concentrations (C max ) and area under the plasma concentration-time curve (AUC)…
Worked on STAVUDINE; LAMIVUDINE; NEVIRAPINE at Aspen Pharmacare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.